FDA Allows Pediatric Enrollment in Phase 1/2 Trial of FCX-007 Gene Therapy for RDEB – Epidermolysis Bullosa News
|
FDA Allows Pediatric Enrollment in Phase 1/2 Trial of FCX-007 Gene Therapy for RDEB
Epidermolysis Bullosa News The U.S. Food and Drug Administration (FDA) will allow pediatric patients to enroll in the Phase 2 segment of an ongoing trial to evaluate FCX-007 as a potential gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), Fibrocell Science … |
